Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes Seven RNAi-Related Patent Applications: Jul 27, 2006

Premium
Title: Compounds and Processes for Single-Pot Attachment of a Label to siRNA
 
Number: 20060167239
 
Filed: Jan. 20, 2006
 
Lead Inventor: Paul Slattum, Mirus
 
The patent application, its abstract states, covers “compounds and methods … for a single-pot covalent attachment of a label to an siRNA comprising forming a covalently attachable labeling reagent for alkylating the molecule. Then, combining the covalently attachable labeling reagent with a mixture containing the molecule, under conditions wherein the labeling reagent has reactivity with the molecule thereby forming a covalent bond.”

Title: RNAi Modulation of RSV and Therapeutic Uses Thereof
 
Number: 20060166921
 
Filed: Jan. 6, 2006
 
Inventor: Rachel Meyers, Alnylam Pharmaceuticals
 
The invention “is based on the in vivo demonstration that RSV can be inhibited through intranasal administration of iRNA agents as well as by parenteral administration of such agents,” the patent application’s abstract states. “Further, it is shown that effective viral reduction can be achieved with more than one virus being treated concurrently. Based on these findings, the … invention provides general and specific compositions and methods that are useful in reducing RSV mRNA levels, RSV protein levels and viral titers in a subject, e.g., a mammal, such as a human. These findings can be applied to other respiratory viruses.”

Title: Oligonucleotide-Based Therapeutics
 
Number: 20060166920
 
Filed: Dec. 27, 2005
 
Lead Inventor: Liang Xu, University of Michigan
 
The invention, the patent application’s abstract states, “relates to compositions comprising dsRNA. In particular, the present invention provides dsRNA comprising nucleotide sequence that is selectively complementary to bcl-xL mRNA sequence and that is not selectively complementary to bcl-xS mRNA sequence, recombinant nucleic acid comprising a vector and nucleic acid sequence for expressing bcl-xL dsRNA, pharmaceutical compositions comprising bcl-xL dsRNA, kits comprising such compositions, and methods of using the same in research, therapeutic, diagnostic, and/or drug screening applications.”

Title: RNAi Inhibition of CTGF for Treatment of Ocular Disorders
 
Number: 20060166919
 
Filed: Dec. 19, 2005
 
Lead Inventor: Allan Shepard, Alcon
 
“RNA interference is provided for inhibition of connective tissue growth factor mRNA expression in ocular disorders involving CTGF expression,” the patent application’s abstract states. “Ocular disorders involving aberrant CTGF expression include glaucoma, macular degeneration, diabetic retinopathy, choroidal neovascularization, proliferative vitreoretinopathy, and wound healing. Such disorders are treated by administering interfering RNAs of the … invention.”

Title: RNAi Modulation of MLL-AF4 and Uses Thereof
 
Number: 20060166918
 
Filed: Dec. 14, 2005
 
Lead Inventor: Olaf Heidenreich, Alnylam Europe
 
“The invention relates to compositions and methods for modulating the expression of the MLL-AF4 fusion gene, and more particularly to the downregulation of MLL-AF4 by chemically modified oligonucleotides,” the patent application’s abstract states.

Title: Process for Producing siRNA
 
Number: 20060166913
 
Filed: Jan. 7, 2004 PCT Filed: Jan. 7, 2004
 
Inventor: Tsutomu Suzuki, University of Tokyo
 
The invention covers “an inexpensive and simple method for transcription and synthesis of siRNA,” the patent application’s abstract states. “The … invention provides an oligonucleotide, which at least comprises, in a direction from the 5'-terminus to the 3'-terminus: an antisense sequence of a target nucleic acid sequence; a trimming sequence which is cleaved with base-specific RNase; a sense sequence of a target nucleic acid sequence; an antisense sequence of a promoter sequence; a sequence that forms a loop; and a sense sequence of a promoter sequence, wherein the above-described antisense sequence and sense sequence of a promoter sequence form a double strand in a molecule via a hairpin structure, and when DNA is transcribed, a transcriptional product from the above-described antisense sequence and sense sequence of a target nucleic acid sequence forms a double strand in a molecule via the trimming sequence.”

Title: RNA Interference by Single-Stranded RNA Molecules
 
Number: 20060166910
 
Filed: July 10, 2003 PCT Filed: July 10, 2003
 
Lead Inventor: Thomas Tuschl, Max Planck
 
The invention “relates to sequence and structural features of single-stranded RNA molecules required to mediate target-specific nucleic acid modifications by RNA interference, such as target mRNA degradation and/or DNA methylation,” the patent application’s abstract states.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.